PTGS2 and Alzheimer disease: Conversely, rosiglitazone modulates microglia phenotype, promoting a shift to a ramified morphology expressing Ym1 and Fizz1 markers in APP transgenic mice [92], thereby reducing TNF-α, COX-2, IL-1ß and interferon gamma (IFN-γ) levels [92, 111], and decreasing CD11b+ microglia colocalization with Aß plaques [93] in both transgenic and Aß-injected AD models.